Crestor - Astrazeneca | Article One Partners
One moment please.

You are using unknown unknown. Some features may not be supported and the experience may be degraded using an older browser.

industry icon Crestor - Astrazeneca

Crestor is the brand name drug sold by AstraZeneca of the drug rosuvastatin calcium. It is a lipid-lowering agent for oral administration.


The patent in this study is a reissue of US 5,260,444. The reissue application was filed on August 27, 1998, more than 2 years after the ‘444 Patent issued. A reissue patent application filed more than 2 years after issuance can only seek to narrow the claims of the original patent. The only claims allowed in the reissue application were claims 6, 7 and 8. Therefore Re37,314 only covers the specific compound of claim 6 and the sodium or calcium salts thereof.

During the prosecution of the reissue application, the applicant successfully argued that the chemical composition shown in claim 6 was not anticipated or obvious. A copy of the imaged filewrapper is available on the USPTO website. You can access the filewrapper by using the PAIR function at the USPTO site.

The chemical name for rosuvastatin calcium is bis[(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid] calcium salt.

Study Downloads

Research Requirements:

Latest Date for Responses
Relevant Patent Dates
US Patent Date
Priority Date
US Application Date
Priority Date
EP Date
Publication Date
Other Patent Authorities
Publication Date
See the claims in the downloadable copies of the patent.